Welcome to The Symptoms Of Multiple Sclerosis
Info On Multiple Sclerosis Article
This is a selection among article about Info On Multiple Sclerosis. For a permanent link to this article, or to bookmark it for further reading, click here.
New Therapies Bring Hope And Quality-Of-Life To MS Patients
from: By: News Canada(NC)-One of the most devastating pieces of news a younger person can be given is that they have an incurable, progressive disease. Sadly, this happens every day to an average of three Canadians between the ages of 20 and 40 when they are diagnosed with Multiple Sclerosis (MS). In fact, Canada has one of the highest rates of MS in the world. More than 50,000 Canadians suffer from this disabling disease of the nervous system.
Multiple Sclerosis means "many scars" and occurs when a person's own immune system damages myelin, the insulation that surrounds and protects nerve fibres. While MS is not fatal for the majority of people who have it, it can cause loss of balance, problems with movement, impaired speech, extreme fatigue, vision difficulty and eventually paralysis. The good news is that with new therapies and the improvement of treatments, people with MS can lead full and healthy lives.
In a recent "real world" study on MS treatments, patients reported enjoying an improved quality-of-life by adhering to specific therapeutic treatments. For example, those treated with a once-a-week therapy called Avonex® (interferon beta-1a) were more than twice as likely to adhere to their therapy than patients on other more frequently taken MS drugs.
"There has been an ongoing debate in the neurology community as to whether weekly or more frequent treatments are better from a clinical standpoint, but what is important to keep in mind is that no drug will work in the real world if patients fail to comply with their treatment regimen," says Dr. Jean-Pierre H. Côté, an MS Specialist in Montréal.
The study showed only 18 per cent of Avonex® patients reported ever missing an injection versus 45 per cent of non-Avonex® patients. In addition, almost three times as many Avonex® patients said they never experienced injection site reactions like itchiness, pain or redness; and, they reported feeling initial flu-like symptoms much less frequently (3.65 times per month) than patients on other interferon therapies (9.02 times).
The Multiple Sclerosis Society of Canada has proclaimed May MS Awareness Month and on Mother's Day weekend (May 10 - 12), thousands of volunteers will sell carnations to the Canadian public to raise funds and awareness for this devastating disease.
About The Author News Canada provides a wide selection of current, ready-to-use copyright free news stories and ideas for Television, Print, Radio, and the Web. News Canada is a niche service in public relations, offering access to print, radio, television, and now the Internet media, with ready-to-use, editorial "fill" items. Monitoring and analysis are two more of our primary services. The service supplies access to the national media for marketers in the private, the public, and the not-for-profit sectors. Your corporate and product news, consumer tips and information are packaged in a variety of ready-to-use formats and are made available to every Canadian media organization including weekly and daily newspapers, cable and commercial television stations, radio stations, as well as the Web sites Canadians visit most often. Visit News Canada and learn more about the NC services. |
This article was posted on August 4, 2002
Info On Multiple Sclerosis News
Alberta ponders paying for new MS treatment - CBC.ca
 CBC.ca | Alberta ponders paying for new MS treatment CBC.ca Dr. Paolo Zamboni, seen here in April, has theorized that multiple sclerosis is triggered by cerebral vascular problems and can be treated by unblocking ... Province cautious on trials for multiple sclerosis therapy Local woman supports controversial MS treatment Sask. plan to fund MS treatment trials raises debate across Canada |
Multiple Sclerosis Drug Granted Priority Review Status by FDA - DrugWatch.com
Multiple Sclerosis Drug Granted Priority Review Status by FDA DrugWatch.com Cladribine, a multiple sclerosis drug manufactured by Merck KGaA, has been granted priority review status by the US Food and Drug administration (FDA), ... Merck KGaA Says FDA Grants Priority Review to Multiple Sclerosis Drug Merck KGaA's Cladribine Gets FDA Priority Review Status FDA oks Merck KGaA's reworked MS pill application |
Analysis: Past deals provide little help in valuing Genzyme - Reuters
 Reuters UK | Analysis: Past deals provide little help in valuing Genzyme Reuters In arguing for a higher price, Genzyme will point to that recovery and to its promising product pipeline, especially its multiple sclerosis drug. ... 'Right Price' Will Get Genzyme Deal Done Sanofi set to make offer for Genzyme Matthew Herper is a senior editor at Forbes |
Lindsay Lohan leaving jail, on to rehab - Examiner.com
 Examiner.com | Lindsay Lohan leaving jail, on to rehab Examiner.com ... by Hilton claiming how the incident changed her and that she was going "to help raise money for kids and for breast cancer and multiple sclerosis. ... |
Anti-hypertensive drug improves multiple sclerosis-related brain inflammation - Sify
Anti-hypertensive drug improves multiple sclerosis-related brain inflammation Sify The researchers know that angiotensin transfers its information to the cell via an increase in the messenger substance Transforming Growth Factor beta (TGF ... |
Small business development & consulting firm.